Trump Announces 100% Tariff on Generic Drug Imports
U.S. President Donald Trump announced that the United States will impose a 100% tariff on imported generic medicines beginning in 2028.
The policy is intended to encourage pharmaceutical companies to move generic drug production to the United States.
Generic Drugs Remain Exempt for Two Years
In a post on Truth Social, Trump said generic pharmaceutical imports would remain exempt from tariffs for the next two years.
Once that exemption ends, imported generic drugs will face a 100% duty.
Trump also said the tariff could later increase to 200%. However, he did not provide a specific date for the higher rate.
White House Seeks to Reshore Drug Production
Trump said the measure would give pharmaceutical companies time to build manufacturing plants and purchase production equipment in the United States.
Companies that fail to establish domestic operations within the stated period would face the new import tariffs.
The administration believes the policy will reduce U.S. dependence on foreign pharmaceutical suppliers and increase domestic manufacturing capacity.
U.S.-Based Manufacturers Could Receive Exemptions
Pharmaceutical companies building drug production facilities in the United States may qualify for tariff exemptions.
The policy is therefore designed to reward businesses that invest in American factories, jobs and pharmaceutical infrastructure.
Companies that continue relying on overseas production could face significantly higher import costs.
Patented Medicines Already Face Tariffs
Earlier this year, Trump signed a separate proclamation introducing 100% tariffs on imported patented pharmaceutical products.
His administration has also considered tariffs on other pharmaceutical imports as part of its broader trade and industrial policy.
Trump has repeatedly argued that tariffs can encourage major drugmakers to expand production inside the United States.
Drug Pricing Policy Linked to Tariff Relief
The president also connected potential tariff exemptions to his “most favored nation” drug pricing policy.
Under that approach, pharmaceutical companies would be expected to charge American buyers prices comparable to those paid in other countries.
Companies that accept the pricing policy may receive relief from the import tariffs.
Policy Could Reshape the Pharmaceutical Industry
The planned tariffs could lead pharmaceutical companies to review their global supply chains and manufacturing strategies.
Some businesses may decide to expand production in the United States to avoid the additional duties.
However, companies that continue importing generic medicines could face sharply higher costs once the tariffs take effect in 2028.
